Reduced expressions of Fas and Bcl-2 proteins in CD14+ monocytes and normal CD14 soluble levels in juvenile systemic lupus erythematosus.

In order to evaluate Fas and Bcl-2 expressions in CD14+ monocytes, to measure soluble CD14 serum levels and to analyze the relationships with lupus nephritis and disease activity, we enrolled 41 patients with juvenile systemic lupus erythematosus (JSLE) and 27 healthy volunteers. Disease activity was determined by SLEDAI score. Peripheral monocytes were stained for CD14, Fas and Bcl-2 molecules, and cellular expressions were determined by flow cytometry. Soluble CD14 levels were measured by a quantitative ELISA kit. JSLE patients, those with active disease and those with nephritis, presented significantly reduced expressions of Fas and Bcl-2 proteins in CD14+ monocytes compared with healthy controls. Significant inverse correlations between percentages of CD14+Fas+ cells, SLEDAI score and anti-dsDNA antibodies were observed. JSLE patients had soluble CD14 levels similar to controls, although sCD14 levels positively correlated with ESR, but not with SLEDAI score. JSLE patients with nephritis also presented sCD14 levels similar to controls. In conclusion, the reduced expressions of Fas and Bcl-2 proteins in CD14+ monocytes from JSLE patients depict that monocyte apoptotic mechanisms may be important in lupus pathogenesis.

MHC class I and II expression in juvenile dermatomyositis skeletal muscle.

OBJECTIVE: To assess MHC I and II expressions in muscle fibres of juvenile dermatomyositis (JDM) and compare with the expression in polymyositis (PM), dermatomyositis (DM) and dystrophy. PATIENTS AND METHODS: Forty-eight JDM patients and 17 controls (8 PM, 5 DM and 4 dystrophy) were studied. The mean age at disease onset was 7.1+/-3.0 years and the mean duration of weakness before biopsy was 9.4+/-12.9 months. Routinehistochemistry and immunohistochemistry (StreptABComplex/HRP) for MHC I and II (Dakopatts) were performed on serial frozen muscle sections in all patients. Mann-Whitney, Kruskal Wallis, chi-square and Fisher's exact statistical methods were used. RESULTS: MHC I expression was positive in 47 (97.9%) JDM cases. This expression was observed independent of time of disease, corticotherapy previous to muscle biopsy and to the grading of inflammation observed in clinical, laboratorial and histological parameters. The expression of MHC I was similar on JDM, PM and DM, and lower in dystrophy. On the other hand, MHC II expression was positive in just 28.2% of JDM cases and was correlated to histological features as inflammatory infiltrate, increased connective tissue and VAS for global degree of abnormality (p<0.05). MHC II expression was similar in DM/PM and lower in JDM and dystrophy, and it was based on the frequency of positive staining rather than to the degree of the MCH II expression. CONCLUSIONS: MHC I expression in muscle fibres is a premature and late marker of JDM patient independent to corticotherapy, and MHC II expression was lower in JDM than in PM and DM.

HLA-DRB1 alleles in juvenile-onset systemic lupus erythematosus: renal histologic class correlations

Human leukocyte antigens (HLA) DRB1*03 and DRB1*02 have been associated with systemic lupus erythematosus (SLE) in Caucasians and black populations. It has been observed that certain HLA alleles show stronger associations with SLE autoantibodies and clinical subsets, although they have rarely been associated with lupus renal histologic class. In the present study, HLA-DRB1 allele correlations with clinical features, autoantibodies and renal histologic class were analyzed in a cohort of racially mixed Brazilian patients with juvenile-onset SLE. HLA-DRB1 typing was carried out by polymerase chain reaction amplification with sequence-specific primers using genomic DNA from 55 children and adolescents fulfilling at least four of the American College of Rheumatology criteria for SLE. Significance was determined by the chi-square test applied to 2 x 2 tables. The HLA-DRB1*15 allele was most frequent in patients with renal, musculoskeletal, cutaneous, hematologic, cardiac, and neuropsychiatric involvement, as well as in patients positive for anti-dsDNA, anti-Sm, anti-U1-RNP, and anti-SSA/Ro antibodies, although an association between HLA alleles and SLE clinical features and autoantibodies could not be observed. The HLA-DRB1*17, HLA-DRB1*10, HLA-DRB1*15, and HLA-DRB1*07 alleles were significantly higher in patients with renal histologic class I, class IIA, class IIB, and class V, respectively. The present results suggest that the contribution of HLA- DRB1 alleles to juvenile-onset SLE could not be related to clinical or serological subsets of the disease, but it may be related to renal histologic classes, especially class I, class II A, class II B, and class V. The latter correlations have not been observed in literature.

Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).

OBJECTIVE: Rituximab, a monoclonal antibody against B-lymphocytes that express CD 20, is already available for the treatment of non-Hodgkin's lymphoma. Due to the increased relevance of B-cell regulation in the pathogenesis of autoimmune diseases, rituximab is being used in the treatment of patients whose condition is refractory to conventional therapy. METHODS: We retrospectively evaluated the short-term efficacy and tolerance of rituximab in patients with various autoimmune diseases who were treated at the Hospital Israelita Albert Einstein in the city of Sao Paulo. RESULTS: During the period 2002-2004, 29 patients with various autoimmune diseases were treated with rituximab 375 mg/m2 for 4 consecutive weeks, or two doses of 1 g 2 weeks apart. We observed remarkable short-term results in all cases, except for one patient with thrombocytopenic purpura. Of note, we describe the results in two patients with diseases not previously treated with rituximab (hypergammaglobulinemic purpura of Waldenstrom and eosinophilic fasciitis with hypergammaglobulinemia). Treatment was well tolerated, with no unexpected adverse events. We also observed a marked reduction in steroid dosage. CONCLUSION: Rituximab seems to be safe and effective in the treatment of patients with a variety of autoimmune diseases that are refractory to other modalities of treatment.

[Quality of life evaluation in children and adolescents with chronic and/or incapacitating diseases: a Brazilian study]. / Evaluación de la calidad de vida en niños y adolescentes portadores de enfermedades crónicas y/o incapacitadoras: un estudio brasileño.

OBJECTIVE: To evaluate quality of life in children and adolescents with acute lymphocytic leukemia (ALL) and juvenile rheumatoid arthritis (JRA). MATERIAL AND METHODS: We administered the Children's Global Assessment Scale (CGAS), the Vineland Adaptative Behavior Scale (VABS) and the Autoquestionnaire qualité de vie enfant imagé (AUQEI) to a sample of 28 children with ALL, 28 children with JRA, and 28 healthy controls, aged 4 to 13 years old, who were diagnosed between 1 and 5 years previously. RESULTS: Slight differences were found in age between patients with ALL and those with JRA. No significant differences were found in time since diagnosis or in CGAS scores. A significant difference was found in VABS global scores, as well as in VABS communication domain scores. No significant differences were found in VABS daily living skills domain scores between patients with ARJ and healthy controls. No significant differences were found among the groups in VABS socialization domain scores or in AUQEI scores. CONCLUSION: In our study, chronically ill children clearly performed worse in adaptative behavior development. Nevertheless, their quality of life was similar to that of healthy controls. Appropriate methods to identify pediatric patients' perception of their illnesses and treatment should be urgently developed.

[Takayasu's arteritis]. / Arteritis de Takayasu.

BACKGROUND: Takayasu's arteritis is a rare vasculitis in the pediatric population that affects the aorta and its branches. There are few studies with an appropriate number of patients and follow-up. OBJECTIVE: To describe the clinical manifestations, laboratory alterations, radiological findings, and treatment in eight children and adolescents with Takayasu's arteritis. METHODS: A retrospective analysis of patients' records from 1990 to 2001 was performed. RESULTS: There were six girls and two boys. The mean age at disease onset was five years and five months. The most common clinical manifestations were systemic findings and cardiovascular, dermatological and neurological abnormalities. In all patients inflammatory activity was high and in three patients the Mantoux test was strongly positive. The most common radiological findings were type IV and V. Treatment included steroids, methotrexate, cyclophosphamide, intravenous gamma globulin, and vascular surgery. Three patients presented sequelae. CONCLUSIONS: Takayasu's arteritis produces considerable morbidity and mortality. To make an early diagnosis, pediatricians should be aware of inflammatory systemic manifestations and cardiovascular abnormalities. To gain further knowledge of this entity prospective and ideally multicenter studies are required.

T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients.

T-cell molecular mimicry between streptococcal and heart proteins has been proposed as the triggering factor leading to autoimmunity in rheumatic heart disease (RHD). We searched for immunodominant T-cell M5 epitopes among RHD patients with defined clinical outcomes and compared the T-cell reactivities of peripheral blood and intralesional T cells from patients with severe RHD. The role of HLA class II molecules in the presentation of M5 peptides was also evaluated. We studied the T-cell reactivity against M5 peptides and heart proteins on peripheral blood mononuclear cells (PBMC) from 74 RHD patients grouped according to the severity of disease, along with intralesional and peripheral T-cell clones from RHD patients. Peptides encompassing residues 1 to 25, 81 to 103, 125 to 139, and 163 to 177 were more frequently recognized by PBMC from RHD patients than by those from controls. The M5 peptide encompassing residues 81 to 96 [M5(81-96) peptide] was most frequently recognized by PBMC from HLA-DR7+ DR53+ patients with severe RHD, and 46.9% (15 of 32) and 43% (3 of 7) of heart-infiltrating and PBMC-derived peptide-reactive T-cell clones, respectively, recognized the M5(81-103) region. Heart proteins were recognized more frequently by PBMC from patients with severe RHD than by those from patients with mild RHD. The similar pattern of T-cell reactivity found with both peripheral blood and heart-infiltrating T cells is consistent with the migration of M-protein-sensitized T cells to the heart tissue. Conversely, the presence of heart-reactive T cells in the PBMC of patients with severe RHD also suggests a spillover of sensitized T cells from the heart lesion.

Skeletal muscle pathology in systemic sclerosis.

OBJECTIVE: Systemic sclerosis (SSc) is characterized by abnormal deposition of collagen in the skin and by visceral involvement. Muscle weakness is a relatively frequent complication of SSc, although severity varies. We studied muscle pathology in patients with SSc with progressive muscle involvement. METHODS: We performed histochemical and immunohistochemical investigations to detect neural cell adhesion molecule (NCAM). RESULTS: Five of the 6 cases of SSc expressed NCAM in atrophic angulated fibers (some fibers stained heavily with oxidative enzymes). CONCLUSION: Neurogenic involvement in SSc is more frequent than reported.

Artrite reumatoide juvenil: estudo de 51 casos. I - Aspectos clinicos. / Juvenile rheumatoid arthritis: study of 51 cases. I - Clinical aspects

Os autores descrevem os achados clinicos em 51 criancas portadoras de artrite reumatoide juvenil atendidas no Instituto da Crianca "Prof. Pedro de Alcantara". Foram analisados: classificacao da doenca, sexo, idade, tipo de artrite, febre, exantema, nodulos subcutaneos, adenomegalia, esplenomegalia, iridociclite, cardite, pleurite e rigidez de nuca

Tratamento da coreia de Sydenham com haloperidol. / Treatment of Sydenham's chorea with haloperidol

Foram estudadas retrospectivamente 39 criancas com coreia de Sydenham recebendo haloperidol como unica medicacao sintomatica A melhora clinica ocorreu em media apos 5,6 dias em todas as criancas; os movimentos coreicos desapareciam em media apos 37 dias e o tempo de tratamento foi de 4,6 meses. Nao foram observadas reacoes graves ou irreversiveis decorrentes do uso de haloperidol

Artrite reumatoide juvenil (ARJ) / Juvenile rheumatoid arthritis

Os autores apresentam um caso de artrite reumatoide juvenil de forma poliarticular soronegativa, diagnosticada em uma crianca de nove anos de idade. O diagnostico foi feito basicamente pelos dados clinicos presentes (poliartrite cronica e deformante em mais de cinco articulacoes) e pelo achado de fator reumatoide negativo

Linfomas nao-Hodgkin na infancia: estudo de 25 casos. Parte I: aspectos clinicos. / Non-Hodgkin's lymphoma in infant: study of 25 cases. Part I: clinical aspects

Os autores estudam 25 criancas com linfomas nao-Hodgkin sob o ponto de vista clinico, radiologico e laboratorial. A idade ao diagnostico variou de 2 a 3 meses a 11 anos, com uma media de 5 anos e 1 mes. Em 64% dos casos a localizacao primaria do tumor foi no abdome, em 28% no mediastino, em 4% nos ganglios perifericos e em 4% no osso (mandibula). Os sintomas variaram dependendo da localizacao primaria do tumor. Encontraram-se poucas alteracoes radiologicas e laboratoriais

Linfoma nao-Hodgkin: estudo de 25 casos.II - Classificacao histopatologica e estadiamento. / Non-Hodgkin's lymphoma: study of 25 cases. II - Histopathological classification and staging

Os autores apresentam 25 pacientes portadoras de linfoma nao-Hodgkin estudados no Instituto da Crianca. No presente trabalho sao apresentados os resultados do ponto de vista histopatologico e estadiamento. Em 48% dos casos, o linfoma era de tipo linfoblastico, em 44% era do tipo histiocitico e em 8%, indiferenciado, tipo Burkitt. Quanto ao estadiamento, a distribuicao foi a seguinte: estadio I, 1 caso; estadio II, 4 casos; estadio III, 19 casos e estadio IV, 1 caso. Os resultados sao comparados com os da literatura